Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2525

1.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
2.

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.

Arch Neurol. 1998 Jul;55(7):937-45.

PMID:
9678311
3.

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.

Arch Neurol. 2001 Mar;58(3):373-9.

PMID:
11255440
4.

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A.

Arch Neurol. 2002 Nov;59(11):1729-34.

PMID:
12433260
5.

Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.

Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA.

Clin Chem. 2010 Feb;56(2):248-53. doi: 10.1373/clinchem.2009.130518. Epub 2009 Oct 15.

6.

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ.

Arch Neurol. 2003 Dec;60(12):1696-702.

PMID:
14676043
7.

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B, Drzezga A, Jahn T, Förstl H, Kurz A.

Neurology. 2002 Jun 11;58(11):1622-8.

PMID:
12058089
8.

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

Maddalena A, Papassotiropoulos A, Müller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C.

Arch Neurol. 2003 Sep;60(9):1202-6.

PMID:
12975284
9.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801
10.

Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.

Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P.

Neurology. 2004 May 11;62(9):1580-4.

PMID:
15136685
11.

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.

Seppälä TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, Pyykkö OT, Helisalmi S, Alafuzoff I, Hiltunen M, Jääskeläinen JE, Rinne J, Soininen H, Leinonen V, Herukka SK.

Neurology. 2012 May 15;78(20):1568-75. doi: 10.1212/WNL.0b013e3182563bd0. Epub 2012 Apr 18.

PMID:
22517093
12.

Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.

Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E.

Arch Neurol. 2010 Feb;67(2):217-23. doi: 10.1001/archneurol.2009.316.

PMID:
20142530
13.

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G.

Neurobiol Aging. 2006 Sep;27(9):1202-11. Epub 2005 Aug 8.

PMID:
16085339
14.

Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.

Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, Yamada M.

J Neurol Sci. 2005 Oct 15;237(1-2):61-5.

PMID:
15992827
15.

CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.

Andreasen N, Sjögren M, Blennow K.

World J Biol Psychiatry. 2003 Oct;4(4):147-55. Review.

PMID:
14608585
16.

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.

Sjögren M, Andreasen N, Blennow K.

Clin Chim Acta. 2003 Jun;332(1-2):1-10. Review.

PMID:
12763273
17.

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.

Biol Psychiatry. 2008 Nov 15;64(10):850-5. doi: 10.1016/j.biopsych.2008.02.016. Epub 2008 Apr 8.

PMID:
18395699
18.

Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.

Tapiola T, Pirttilä T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H.

Neurobiol Aging. 2000 Sep-Oct;21(5):735-40.

PMID:
11016543
19.

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

Herukka SK, Hallikainen M, Soininen H, Pirttilä T.

Neurology. 2005 Apr 12;64(7):1294-7.

PMID:
15824371
20.

Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.

Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T.

J Neurol Neurosurg Psychiatry. 2010 Jun;81(6):608-10. doi: 10.1136/jnnp.2009.197483.

PMID:
20522869

Supplemental Content

Support Center